Hims & Hers Health (NYSE:HIMS) Sets New 1-Year High – What’s Next?

Hims & Hers Health, Inc. (NYSE:HIMS) reached a new 52-week high on Wednesday . The company traded as high as $35.02 and last traded at $34.77, with a volume of 5424326 shares trading hands. The stock had previously closed at $30.68.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of analyst reports. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Piper Sandler restated a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Finally, Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $20.71.

Hims & Hers Health Stock Up 1.6 %

The company has a market capitalization of $6.81 billion, a P/E ratio of 79.02 and a beta of 1.06. The firm has a fifty day simple moving average of $20.85 and a 200-day simple moving average of $19.44.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue was up 77.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. This represents a 84.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 101,993 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $29.62, for a total value of $3,021,032.66. Following the transaction, the chief financial officer now directly owns 109,392 shares in the company, valued at $3,240,191.04. This trade represents a 48.25 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,153,519 shares of company stock worth $24,486,721. Corporate insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC increased its position in Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares during the last quarter. Wellington Management Group LLP raised its stake in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after acquiring an additional 883,230 shares during the period. Geode Capital Management LLC raised its stake in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after acquiring an additional 482,177 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Hims & Hers Health by 164.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after purchasing an additional 328,142 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.